Skip to main content

Featured

Wall Street Braces as Tech Rout Deepens

US markets looked set for another turbulent session as futures for the S&P 500 and Nasdaq pointed lower, signaling continued pressure on the tech sector. A wave of selling has swept through major technology names this week, and Thursday’s pre‑market action suggested the downturn isn’t over yet. Alphabet remained a major drag after its sharp slide, with investors reacting to concerns about rising AI‑related spending and the uncertain payoff timeline. The pullback has added to broader anxiety across the sector, where valuations have been tested by shifting expectations around growth and profitability. Amazon now sits in the spotlight as traders await its upcoming earnings report. With sentiment already fragile, the company’s results could either steady the market or accelerate the sell‑off, depending on how its cloud and retail segments perform. Commodities also reflected the risk‑off mood. Silver prices tumbled, extending a recent decline and underscoring the cautious tone acros...
Post a Comment
Read more

article

Labels

New Cystic Fibrosis Drug Offers Hope, but Comes with a High Price

A new drug for cystic fibrosis, Trikafta, is providing significant hope for patients suffering from the genetic disorder. Trikafta has been shown to reduce hospital visits and improve overall lung function, offering patients a better quality of life. For those living with cystic fibrosis, which affects the respiratory and digestive systems, this advancement is nothing short of a breakthrough.

However, the cost of Trikafta is a major concern. Priced at around $300,000 per year, the drug is prohibitively expensive for many patients and their families. While some health programs and insurance plans may cover the cost, access to this life-changing medication remains a challenge.

As the debate over drug pricing and healthcare accessibility continues, the medical community and patient advocacy groups are calling for measures to ensure that Trikafta is available to all who need it, regardless of their financial situation.


Labels:

Comments

Post a Comment